Home > Boards > US Listed > Biotechs > Portola Phramaceuticals (PTLA)

And PTLA beats on revenue!

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
H2R Member Profile
 
Followed By 22
Posts 1,763
Boards Moderated 0
Alias Born 07/17/14
160x600 placeholder
Termination of Registration of a Class of Security Under Section 12(b) (15-12b) Edgar (US Regulatory) - 7/13/2020 8:30:49 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/7/2020 3:40:31 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2020 5:56:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2020 5:55:30 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2020 5:46:03 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2020 5:41:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2020 5:38:18 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2020 5:38:12 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2020 5:35:41 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2020 5:29:30 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2020 5:29:23 PM
Post-effective Amendment to an Automatic Shelf Registration of Form S-3asr or Form F-3asr (posasr) Edgar (US Regulatory) - 7/2/2020 2:33:20 PM
Post-effective Amendment to an S-8 Filing (s-8 Pos) Edgar (US Regulatory) - 7/2/2020 2:33:04 PM
Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ... Edgar (US Regulatory) - 7/2/2020 2:32:42 PM
Post-effective Amendment to an S-8 Filing (s-8 Pos) Edgar (US Regulatory) - 7/2/2020 2:31:38 PM
Post-effective Amendment to an S-8 Filing (s-8 Pos) Edgar (US Regulatory) - 7/2/2020 2:31:04 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/2/2020 2:28:31 PM
Amended Tender Offer Statement by Third Party (sc To-t/a) Edgar (US Regulatory) - 6/25/2020 9:28:26 AM
Amended Statement of Ownership: Solicitation (sc 14d9/a) Edgar (US Regulatory) - 6/25/2020 9:27:20 AM
H2R   Friday, 03/01/19 10:17:01 AM
Re: H2R post# 170
Post # of 196 
And PTLA beats on revenue!

https://seekingalpha.com/news/3439056-portola-pharmaceuticals-beats-0_07-beats-revenue


and

http://investors.portola.com/phoenix.zhtml?c=198136&p=irol-newsArticle&ID=2389690


Quote:
Portola Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

– Fourth Quarter Andexxa® Revenues of $14.0 Million; Third Consecutive Quarter of Strong Revenues –

– Received Positive CHMP Opinion on Ondexxya™; European Commission Decision Anticipated in Early May –

– Signed $125 Million Loan Agreement with HealthCare Royalty Partners and Athyrium Capital Management –

[...]

Total revenues for the fourth quarter of 2018 were $15.3 million, compared with $9.8 million for the fourth quarter of 2017. This includes $14.0 million in net product revenues from Andexxa sales, $35 thousand in revenues from Bevyxxa® sales and $1.2 million in collaboration and license revenues. Total revenues for the full year 2018 were $40.1 million, compared with $22.5 million for the full year 2017. Please see the tables at the end of this press release for a detailed breakdown of revenues.




They are moving!

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences